Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance

Behrooz, Amir Barzegar; Vazifehmand, Reza; Tajudin, Asilah Ahmad; Masomian, Malihe; Syahir, Amir

doi:10.1007/s13346-021-01017-1

Cited by 15 publications

(11 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the co-delivery of both TMZ and idasanutlin effectively increased the cytotoxicity percentage from ~ 10% with TMZ-loaded nanoparticles up to 80% with TMZ and idasanutlin targeted nanoparticles. A more recent study carried out by Behrooz et al 74 demonstrated a higher killing capacity of CD133 targeted polymeric nanoparticles together with higher nanoparticle accumulation in U87 stem cells. In this case, they also conjugated an aptamer against CD133 to polymeric nanoparticles, and they co-loaded TMZ with paclitaxel 74 .…”

Section: Improving Gbm Limitationsmentioning

confidence: 94%

“…Several studies have reported that polymer-based nanosystems could be used to co-encapsulate TMZ with other chemotherapies including doxorubicin 37 , paclitaxel 74 and 5-Fluoracil 39 . In studies carried out by Di Martino 37 , 39 , both doxorubicin and 5-Fluoracil were co-encapsulated with TMZ in polymeric NPs.…”

Section: Improving Tmz Limitationsmentioning

confidence: 99%

“…In studies carried out by Di Martino 37 , 39 , both doxorubicin and 5-Fluoracil were co-encapsulated with TMZ in polymeric NPs. Behrooz et al, on the other hand, used dendrimers composed of PAMAM to deliver TMZ with paclitaxel to U87 CD133+ and CD44+ stem cells 74 . They demonstrated that this nanosystem was able to increase the early apoptosis from 28.2% in the case of the administration of the free drug, up to 73.3% with the encapsulated co-delivery.…”

Section: Improving Tmz Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment

Iturrioz-Rodríguez¹,

Samprón²,

Matheu³

2023

Theranostics

View full text Add to dashboard Cite

Glioblastoma is the most common and lethal brain tumor in adults. The incorporation of temozolomide (TMZ) into the standard treatment has increased the overall survival rate of glioblastoma patients. Since then, significant advances have been made in understanding the benefits and limitations of TMZ. Among the latter, the unspecific toxicity of TMZ, poor solubility, and hydrolyzation are intrinsic characteristics, whereas the presence of the blood-brain barrier and some tumor properties, such as molecular and cellular heterogeneity and therapy resistance, have limited the therapeutic effects of TMZ in treating glioblastoma. Several reports have revealed that different strategies for TMZ encapsulation in nanocarriers overcome those limitations and have shown that they increase TMZ stability, half-life, biodistribution, and efficacy, offering the promise for future nanomedicine therapies in handling glioblastoma. In this review, we analyze the different nanomaterials used for the encapsulation of TMZ to improve its stability, blood half-life and efficacy, paying special attention to polymer- and lipid-based nanosystems. To improve TMZ drug resistance, present in up to 50% of patients, we detail TMZ combined therapeutic with i) other chemotherapies, ii) inhibitors, iii) nucleic acids, iv) photosensitizers and other nanomaterials for photodynamic therapy, photothermal therapy, and magnetic hyperthermia, v) immunotherapy, and vi) other less explored molecules. Moreover, we describe targeting strategies, such as passive targeting, active targeting to BBB endothelial cells, glioma cells, and glioma cancer stem cells, and local delivery, where TMZ has demonstrated an improved outcome. To finish our study, we include possible future research directions that could help decrease the time needed to move from bench to bedside.

show abstract

Section: Improving Gbm Limitationsmentioning

confidence: 94%

Section: Improving Tmz Limitationsmentioning

confidence: 99%

Section: Improving Tmz Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment

Iturrioz-Rodríguez¹,

Samprón²,

Matheu³

2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…However, this study was not perfect, and in vivo experiments are necessary to further clarify the results ( Fig. 3 C) [ 89 ]. In another study, to enhance the efficacy of TMZ, polymer-micellar nanoparticles were developed for the co-delivery of TMZ and RG7388 (an inhibitor of glioblastoma multiforme DNA damage response systems) and covalently bound to the CD133 aptamer to target CSCs.…”

Section: Multifunctional Csc-targeted Aptamer-based Therapeuticsmentioning

confidence: 99%

Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells

Liu¹,

Hu²,

Xiang³

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

“…In addition, co-delivering the drugs for regulating DNA damage or inhibiting drug efflux, specifically inducing GSCs apoptosis, is another practical approach. Behrooz et al 65 designed B19 aptamer-conjugated dendrimer nanoparticles to co-deliver paclitaxel (PTX) and TMZ (denoted Apt-NPs). Owing to the high affinity between B19 aptamer and CD133, a most recognizable biomarker on GSCs, Apt-NPs target U-87 stem cells and induce apoptosis, further reducing the resistance in GBM.…”

Section: Nanomedicine-based Combination Therapies To Overcome Drug Re...mentioning

confidence: 99%

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

Wang

Xiao

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common malignant brain tumor. Although current treatment strategies, including surgery, chemotherapy, and radiotherapy, have achieved clinical effects and prolonged the survival of patients, the gradual development of resistance against current therapies has led to a high recurrence rate and treatment failure. Mechanisms underlying the development of resistance involve multiple factors, including drug efflux, DNA damage repair, glioma stem cells, and a hypoxic tumor environment, which are usually correlative and promote each other. As many potential therapeutic targets have been discovered, combination therapy that regulates multiple resistance-related molecule pathways is considered an attractive strategy. In recent years, nanomedicine has revolutionized cancer therapies with optimized accumulation, penetration, internalization, and controlled release. Blood-brain barrier (BBB) penetration efficiency is also significantly improved through modifying ligands on nanomedicine and interacting with the receptors or transporters on the BBB. Moreover, different drugs for combination therapy usually process different pharmacokinetics and biodistribution, which can be further optimized with drug delivery systems to maximize the therapeutic efficiency of combination therapies. Herein the current achievements in nanomedicine-based combination therapy for GBM are discussed. This review aimed to provide a broader understanding of resistance mechanisms and nanomedicine-based combination therapies for future research on GBM treatment.

show abstract

Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance

Cited by 15 publications

References 82 publications

Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment

Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment

Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

Contact Info

Product

Resources

About